|
EXHIBIT
99.2
|
|
PRESS
RELEASE DATED AUGUST 4, 2010
|
ProPhase
Labs, Inc. to Release Second Quarter Results on Thursday, August 12
DOYLESTOWN,
Pennsylvania – August 4, 2010. ProPhase Labs (Nasdaq: PRPH) announced
today that financial results for the second quarter, ended June 30, 2010, will
be released before market open on August 12, 2010. An earnings conference call
will be held later that morning on Thursday August 12th, at
11:00am EDT. ProPhase Chairman and CEO, Ted Karkus, and COO/CFO Robert
Cuddihy will provide a Company overview including a review of activities and
second quarter results. There will be a question and answer session following
initial remarks.
The
conference call will be webcast live at
http://event.meetingstream.com/r.htm?e=230018&s=1&k=F4BB5B1CDF7D0376F5A5606741F4CF85 at
11:00 AM (EDT) on Thursday August 12, 2010.
Participants
wishing to ask questions may access the live call by dialing (877) 217– 6026
conference ID
# 89801300. A
replay of the conference call will be available for 90 days on the Company web
site at www.prophaselabs.com.
About
ProPhase Labs
ProPhase
Labs is a diversified natural health medical science company. It is a
leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar
free tablets clinically proven to significantly reduce the severity and duration
of the common cold. Cold-EEZE customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies. ProPhase Labs has several wholly owned subsidiaries
including a manufacturing unit, which consists of an FDA approved facility to
manufacture Cold-EEZE lozenges and fulfill other contract manufacturing
opportunities, and a Pharma division, which conducts research in order to
develop and commercialize a pipeline of patented botanical and naturally derived
potential prescription drugs. ProPhase also owns 50% of Phusion
Laboratories LLC (“Phusion”). Phusion licenses a revolutionary
proprietary technology that has the potential to improve the delivery and/or
efficacy of many active ingredients or compounds. The joint venture
will formulate and test products to exploit market opportunities within
ProPhase’s robust OTC distribution channels.
For more
information visit us at www.ProPhaseLabs.com.
CONTACT
Media
Relations
The
Lexicomm Group
Wendi
Tush
Wendi@lexicommgroup.com
(212)
794-4531
Lindsey
Gardner
Lindsey@lexicommgroup.com
(570)
479-4895
Investor
Relations
Ted
Karkus
Chairman
of the Board, CEO
(215)
345-0919 x0